Top

Published in:

Open Access 01-12-2023 | Kidney Cancer | Research

Serum extracellular vesicles derived hsa-miR-320d as an indicator for progression of clear cell renal cell carcinoma

Authors: Yizheng Xue, Tianyi Chen, Naiqiao Hou, Xiaorong Wu, Wen Kong, Jiwei Huang, Jin Zhang, Yonghui Chen, Junhua Zheng, Wei Zhai, Wei Xue

Published in: Discover Oncology | Issue 1/2023

Abstract

Background

Renal cell carcinoma (RCC) is a prevalent malignancy with a rising incidence in developing countries. Clear cell renal cell carcinoma (ccRCC) constitutes 70% of RCC cases and is prone to metastasis and recurrence, yet lacks a liquid biomarker for surveillance. Extracellular vesicles (EVs) have shown promise as biomarkers in various malignancies. In this study, we investigated the potential of serum EV-derived miRNAs as a biomarker for ccRCC metastasis and recurrence.

Materials and methods

Patients diagnosed with ccRCC between 2017 and 2020 were recruited in this study. In the discovery phase, high throughput small RNA sequencing was used to analyze RNA extracted from serum EVs derived from localized ccRCC (LccRCC) and advanced ccRCC (AccRCC). In the validation phase, qPCR was employed for quantitative detection of candidate biomarkers. Migration and invasion assays were performed on ccRCC cell line OSRC2.

Results

Serum EVs derived hsa-miR-320d was significantly up-regulated in patients with AccRCC than in patients with LccRCC (p < 0.01). In addition, Serum EVs derived hsa-miR-320d was also significantly up-regulated in patients who experienced recurrence or metastasis (p < 0.01). Besides, hsa-miR-320d enhances the pro-metastatic phenotype of ccRCC cells in vitro.

Conclusions

Serum EVs derived hsa-miR-320d as a liquid biomarker exhibits significant potential for identifying the recurrence or metastasis of ccRCC, as well as hsa-miR-320d promotes ccRCC cells migration and invasion.

Available only for authorised users

Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. https://doi.org/10.3322/caac.21708.CrossRefPubMed

Usher-Smith J, Simmons RK, Rossi SH, Stewart GD. Current evidence on screening for renal cancer. Nat Rev Urol. 2020;17(11):637–42. https://doi.org/10.1038/s41585-020-0363-3.CrossRefPubMedPubMedCentral

Young MD, Mitchell TJ, Vieira Braga FA, et al. Single-cell transcriptomes from human kidneys reveal the cellular identity of renal tumors. Science. 2018;361(6402):594–9. https://doi.org/10.1126/science.aat1699.CrossRefPubMedPubMedCentral

Hsieh JJ, Purdue MP, Signoretti S, et al. Renal cell carcinoma. Nat Rev Dis Primers. 2017;3:17009. https://doi.org/10.1038/nrdp.2017.9.CrossRefPubMedPubMedCentral

Jamil ML, Keeley J, Sood A, et al. Long-term risk of recurrence in surgically treated renal cell carcinoma: a post hoc analysis of the eastern cooperative oncology group-American College of Radiology Imaging Network E2805 Trial Cohort. Eur Urol. 2020;77(2):277–81. https://doi.org/10.1016/j.eururo.2019.10.028.CrossRefPubMed

Thurairaja R, Studer UE, Burkhard FC. Indications, extent, and benefits of pelvic lymph node dissection for patients with bladder and prostate cancer. Oncologist. 2009;14(1):40–51. https://doi.org/10.1634/theoncologist.2008-0123.CrossRefPubMed

Dudani S, de Velasco G, Wells JC, et al. Evaluation of clear cell, papillary, and chromophobe renal cell carcinoma metastasis sites and association with survival. JAMA Netw Open. 2021;4(1):e2021869. https://doi.org/10.1001/jamanetworkopen.2020.21869.CrossRefPubMedPubMedCentral

Zomer A, Maynard C, Verweij FJ, et al. In Vivo imaging reveals extracellular vesicle-mediated phenocopying of metastatic behavior. Cell. 2015;161(5):1046–57. https://doi.org/10.1016/j.cell.2015.04.042.CrossRefPubMedPubMedCentral

Ficarra V, Novara G, Galfano A, et al. The “Stage, Size, Grade and Necrosis” score is more accurate than the University of California Los Angeles Integrated Staging System for predicting cancer-specific survival in patients with clear cell renal cell carcinoma. BJU Int. 2009;103(2):165–70. https://doi.org/10.1111/j.1464-410X.2008.07901.x.CrossRefPubMed

10.

Marchioni M, Rivas JG, Autran A, et al. Biomarkers for renal cell carcinoma recurrence: state of the art. Curr Urol Rep. 2021;22(6):31. https://doi.org/10.1007/s11934-021-01050-0.CrossRefPubMedPubMedCentral

11.

Tkach M, Théry C. Communication by extracellular vesicles: where we are and where we need to go. Cell. 2016;164(6):1226–32. https://doi.org/10.1016/j.cell.2016.01.043.CrossRefPubMed

12.

Rahbarghazi R, Jabbari N, Sani NA, et al. Tumor-derived extracellular vesicles: reliable tools for Cancer diagnosis and clinical applications. Cell Commun Signal. 2019;17(1):73. https://doi.org/10.1186/s12964-019-0390-y.CrossRefPubMedPubMedCentral

13.

Patel G, Agnihotri TG, Gitte M, et al. Exosomes: a potential diagnostic and treatment modality in the quest for counteracting cancer. Cell Oncol (Dordr). 2023. https://doi.org/10.1007/s13402-023-00810-z.CrossRefPubMed

14.

Wortzel I, Dror S, Kenific CM, Lyden D. Exosome-mediated metastasis: communication from a distance. Dev Cell. 2019;49(3):347–60. https://doi.org/10.1016/j.devcel.2019.04.011.CrossRefPubMed

15.

Rezaie J, Ahmadi M, Ravanbakhsh R, et al. Tumor-derived extracellular vesicles: the metastatic organotropism drivers. Life Sci. 2022;289:120216. https://doi.org/10.1016/j.lfs.2021.120216.CrossRefPubMed

16.

Mao W, Wang K, Wu Z, Xu B, Chen M. Current status of research on exosomes in general, and for the diagnosis and treatment of kidney cancer in particular. J Exp Clin Cancer Res. 2021;40(1):305. https://doi.org/10.1186/s13046-021-02114-2.CrossRefPubMedPubMedCentral

17.

Qu L, Ding J, Chen C, et al. Exosome-transmitted lncARSR promotes sunitinib resistance in renal cancer by acting as a competing endogenous RNA. Cancer Cell. 2016;29(5):653–68. https://doi.org/10.1016/j.ccell.2016.03.004.CrossRefPubMed

18.

Hu G, Ma J, Zhang J, et al. Hypoxia-induced lncHILAR promotes renal cancer cell invasion and metastasis via ceRNA for the miR-613/206/1–1–3p/Jagged-1/Notch/CXCR4 signaling pathway. Mol Ther. 2021. https://doi.org/10.1016/j.ymthe.2021.05.020.CrossRefPubMedPubMedCentral

19.

Wang L, Yang G, Zhao D, et al. CD103-positive CSC exosome promotes EMT of clear cell renal cell carcinoma: role of remote MiR-19b-3p. Mol Cancer. 2019;18(1):86. https://doi.org/10.1186/s12943-019-0997-z.CrossRefPubMedPubMedCentral

20.

Wang X, Wang T, Chen C, et al. Serum exosomal miR-210 as a potential biomarker for clear cell renal cell carcinoma. J Cell Biochem. 2018. https://doi.org/10.1002/jcb.27347.CrossRefPubMedPubMedCentral

21.

Zhang W, Ni M, Su Y, et al. MicroRNAs in serum exosomes as potential biomarkers in clear-cell renal cell carcinoma. Eur Urol Focus. 2018;4(3):412–9. https://doi.org/10.1016/j.euf.2016.09.007.CrossRefPubMed

22.

Fujii N, Hirata H, Ueno K, et al. Extracellular miR-224 as a prognostic marker for clear cell renal cell carcinoma. Oncotarget. 2017;8(66):109877–88. https://doi.org/10.18632/oncotarget.22436.CrossRefPubMedPubMedCentral

23.

Du M, Giridhar KV, Tian Y, et al. Plasma exosomal miRNAs-based prognosis in metastatic kidney cancer. Oncotarget. 2017;8(38):63703–14. https://doi.org/10.18632/oncotarget.19476.CrossRefPubMedPubMedCentral

24.

Butz H, Nofech-Mozes R, Ding Q, et al. Exosomal MicroRNAs are diagnostic biomarkers and can mediate cell-cell communication in renal cell carcinoma. Eur Urol Focus. 2016;2(2):210–8. https://doi.org/10.1016/j.euf.2015.11.006.CrossRefPubMed

25.

Ljungberg B, Albiges L, Abu-Ghanem Y, et al. European Association of Urology Guidelines on renal cell carcinoma: the 2022 update. Eur Urol. 2022. https://doi.org/10.1016/j.eururo.2022.03.006.CrossRefPubMed

26.

Chen X, Gao S, Zhao Z, Liang G, Kong J, Feng X. MicroRNA-320d regulates tumor growth and invasion by promoting FoxM1 and predicts poor outcome in gastric cardiac adenocarcinoma. Cell Biosci. 2020;10:80. https://doi.org/10.1186/s13578-020-00439-7.CrossRefPubMedPubMedCentral

27.

Tang Y, Zhao Y, Song X, Niu L, Xie L. Tumor-derived exosomal miRNA-320d as a biomarker for metastatic colorectal cancer. J Clin Lab Anal. 2019;33(9):e23004. https://doi.org/10.1002/jcla.23004.CrossRefPubMedPubMedCentral

28.

Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet. 2009;373(9669):1119–32. https://doi.org/10.1016/s0140-6736(09)60229-4.CrossRefPubMed

29.

Klatte T, Rossi SH, Stewart GD. Prognostic factors and prognostic models for renal cell carcinoma: a literature review. World J Urol. 2018;36(12):1943–52. https://doi.org/10.1007/s00345-018-2309-4.CrossRefPubMed

30.

Gray RE, Harris GT. Renal cell carcinoma: diagnosis and management. Am Fam Physician. 2019;99(3):179–84.PubMed

31.

Ignatiadis M, Sledge GW, Jeffrey SS. Liquid biopsy enters the clinic - implementation issues and future challenges. Nat Rev Clin Oncol. 2021;18(5):297–312. https://doi.org/10.1038/s41571-020-00457-x.CrossRefPubMed

32.

Chemi F, Rothwell DG, McGranahan N, et al. Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse. Nat Med. 2019;25(10):1534–9. https://doi.org/10.1038/s41591-019-0593-1.CrossRefPubMedPubMedCentral

33.

Zengin ZB, Weipert C, Salgia NJ, et al. Complementary role of circulating tumor DNA assessment and tissue genomic profiling in metastatic renal cell carcinoma. Clin Cancer Res. 2021;27(17):4807–13. https://doi.org/10.1158/1078-0432.CCR-21-0572.CrossRefPubMed

34.

Min L, Zhu S, Chen L, et al. Evaluation of circulating small extracellular vesicles derived miRNAs as biomarkers of early colon cancer: a comparison with plasma total miRNAs. J Extracell Vesicles. 2019;8(1):1643670. https://doi.org/10.1080/20013078.2019.1643670.CrossRefPubMedPubMedCentral

35.

Min L, Chen L, Liu S, et al. Loss of circulating exosomal miR-92b is a novel biomarker of colorectal cancer at early stage. Int J Med Sci. 2019;16(9):1231–7. https://doi.org/10.7150/ijms.34540.CrossRefPubMedPubMedCentral

36.

Guo X, Lv X, Ru Y, et al. Circulating exosomal gastric cancer-associated long noncoding RNA1 as a biomarker for early detection and monitoring progression of gastric cancer: a multiphase study. JAMA Surg. 2020;155(7):572–9. https://doi.org/10.1001/jamasurg.2020.1133.CrossRefPubMedPubMedCentral

37.

Wang Y, Fang YX, Dong B, et al. Discovery of extracellular vesicles derived miR-181a-5p in patient’s serum as an indicator for bone-metastatic prostate cancer. Theranostics. 2021;11(2):878–92. https://doi.org/10.7150/thno.49186.CrossRefPubMedPubMedCentral

38.

Wiklander OPB, Brennan M, Lötvall J, Breakefield XO, ElAndaloussi S. Advances in therapeutic applications of extracellular vesicles. Sci Transl Med. 2019. https://doi.org/10.1126/scitranslmed.aav8521.CrossRefPubMedPubMedCentral

39.

Rezaie J, Feghhi M, Etemadi T. A review on exosomes application in clinical trials: perspective, questions, and challenges. Cell Commun Signal. 2022;20(1):145. https://doi.org/10.1186/s12964-022-00959-4.CrossRefPubMedPubMedCentral

40.

Horie K, Kawakami K, Fujita Y, et al. Exosomes expressing carbonic anhydrase 9 promote angiogenesis. Biochem Biophys Res Commun. 2017;492(3):356–61. https://doi.org/10.1016/j.bbrc.2017.08.107.CrossRefPubMed

41.

Shaban SA, Rezaie J, Nejati V. Exosomes derived from senescent endothelial cells contain distinct pro-angiogenic miRNAs and proteins. Cardiovasc Toxicol. 2022;22(6):592–601. https://doi.org/10.1007/s12012-022-09740-y.CrossRefPubMed

42.

Grange C, Tapparo M, Collino F, et al. Microvesicles released from human renal cancer stem cells stimulate angiogenesis and formation of lung premetastatic niche. Cancer Res. 2011;71(15):5346–56. https://doi.org/10.1158/0008-5472.can-11-0241.CrossRefPubMed

43.

Yang L, Wu X, Wang D, Luo C, Chen L. Renal carcinoma cell-derived exosomes induce human immortalized line of Jurkat T lymphocyte apoptosis in vitro. Urol Int. 2013;91(3):363–9. https://doi.org/10.1159/000348747.CrossRefPubMed

44.

De Palma G, Sallustio F, Curci C, et al. The three-gene signature in urinary extracellular vesicles from patients with clear cell renal cell carcinoma. J Cancer. 2016;7(14):1960–7. https://doi.org/10.7150/jca.16123.CrossRefPubMedPubMedCentral

45.

Bhardwaj A, Singh S, Srivastava SK, et al. Restoration of PPP2CA expression reverses epithelial-to-mesenchymal transition and suppresses prostate tumour growth and metastasis in an orthotopic mouse model. Br J Cancer. 2014;110(8):2000–10. https://doi.org/10.1038/bjc.2014.141.CrossRefPubMedPubMedCentral

46.

Li J, Sheng C, Li W, Zheng JH. Protein phosphatase-2A is down-regulated in patients within clear cell renal cell carcinoma. Int J Clin Exp Pathol. 2014;7(3):1147–53.PubMedPubMedCentral

Title: Serum extracellular vesicles derived hsa-miR-320d as an indicator for progression of clear cell renal cell carcinoma
Authors: Yizheng Xue
Tianyi Chen
Naiqiao Hou
Xiaorong Wu
Wen Kong
Jiwei Huang
Jin Zhang
Yonghui Chen
Junhua Zheng
Wei Zhai
Wei Xue
Publication date: 01-12-2023
Publisher: Springer US
Keywords: Kidney Cancer
Kidney Cancer
Kidney Cancer
Metastasis
Biomarkers
Published in: Discover Oncology / Issue 1/2023
Print ISSN: 1868-8497
Electronic ISSN: 2730-6011
DOI: https://doi.org/10.1007/s12672-023-00730-2

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Background

Materials and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2023

The role of pyroptosis-related lncRNA risk signature in ovarian cancer prognosis and immune system

Correction: 7,8-Dihydroxyflavone induces mitochondrial apoptosis and down-regulates the expression of ganglioside GD3 in malignant melanoma cells

ABHD17C, a metabolic and immune-related gene signature, predicts prognosis and anti-PD1 therapy response in pancreatic cancer

Classification and function of γδT cells and its research progress in anti-glioblastoma

Correction: The relationship of serum gastrin-17 and oral mucositis in head and neck carcinoma patients receiving radiotherapy

Ovarian clear cell carcinoma with or without endometriosis origin in a single institution cohort

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials